Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
about
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's diseasePopulation pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-enPharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.
P2860
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
@ast
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
@en
type
label
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
@ast
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
@en
prefLabel
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
@ast
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
@en
P1433
P1476
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa
@en
P2093
P304
29-32; discussion 57-60
P407
P433
P577
1992-01-01T00:00:00Z